1119 ET - Merck KGaA's acquisition of SpringWorks Therapeutics for $47 per share, or $3.9 billion in total, carried an underwhelming price tag to say the least, Evercore ISI analysts say in a research note. The analysts expected an agreement to price shares in the $60s, which would have still been highly attractive for the buyer, they said. The final deal price net of cash represents just two times the company's consensus peak sales, the analysts said, adding they can't recall such a low multiple for a company not in distress. "Hopefully this transaction is not a broader indictment on the state of biotech M&A amidst a difficult backdrop," the analysts say. (kelly.cloonan@wsj.com)
(END) Dow Jones Newswires
April 28, 2025 11:20 ET (15:20 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。